Inhibition of TNF (↓ TNF level in blood; Afelimomab is safe, biologically active, and well tolerated in patients with severe sepsis, reduces 28-day all-cause mortality, and attenuates the severity of organ dysfunction in patients with elevated interleukin-6 levels). This evidence concerns the gene TNF and Sepsis.